Update on eVOLVE-Lung02 Phase III Trial of Volrustomig Plus Chemotherapy in Metastatic Non-Small Cell Lung Cancer
Phase 3negativevolrustomigpembrolizumabNegative
AI Analysis
Summary
AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as first-line therapy for metastatic non-small cell lung cancer. The trial was comparing volrustomig plus chemotherapy to pembrolizumab plus chemotherapy.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Trial discontinuation
Importance:8/10
Sentiment:
-0.90
Phase IIItrial discontinuationoncologylung cancerimmuno-oncology
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 17, 2026 8:08 PM